The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

Chemotherapy of Delirium Tremens: A Survey of Physicians' Preferences

Published Online:https://doi.org/10.1176/ajp.131.9.1031

Because of the confusion in the literature concerning the chemotherapy of delirium tremens, the authors sent questionnaires to selected experienced physicians throughout the nation. Out of 101 useful responses, 86 physicians chose a benzodiazepine as a primary drug of choice. Of these, 64 favored chlordiazepoxide and 22 favored diazepam. The overall mortality of the patients they treated appeared to be quite low.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.